Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
905.15
+0.18 (+0.02%)
Streaming Delayed Price
Updated: 11:57 AM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eli Lilly
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
February 22, 2023
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.
Via
MarketBeat
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
February 16, 2023
Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029).
Via
SBWire
Gemcitabine HCL Market to Grow with a Growth Rate of 7% During 2023 to 2030
February 10, 2023
Gemcitabine HCL Market size is expected to reach at a CAGR of 7% during the forecast period (2023-2030).
Via
SBWire
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Watch for Continued Gains in Shares of Eli Lilly and Company (LLY)
September 28, 2022
Via
Investor Brand Network
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
February 09, 2023
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)
Via
SBWire
Europe Ovarian Cancer Market Size Share Demand Analysis 2023-2030
February 08, 2023
Global Europe Ovarian Cancer Market to Witness Huge Growth by Key Players: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd,...
Via
SBWire
Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030
February 08, 2023
Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead...
Via
SBWire
Topics
Death
Exposures
Death
Active Pharmaceutical Ingredients Market May Set Epic Growth Story : Pfizer, Novartis, Sanofi
February 07, 2023
Stay up-to-date with Active Pharmaceutical Ingredients Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Topics
Death
Exposures
Death
Is Biotech Immunocore About To Make A 25% Price Move?
February 07, 2023
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.
Via
MarketBeat
Topics
ETFs
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names Seasoned Veteran as New Chief Business Officer
February 03, 2023
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Darryle D. Schoepp, Ph.D., Former Merck and Eli Lilly Executive, Joins Scientific Advisory Board of Akelos Inc., Biotechnology Company Developing Opioid Alternatives
February 01, 2023
NEW YORK, February 1, 2023 (Newswire.com) - Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic...
Via
Newswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Cassava Sciences Stock Undervalued with Its $124 Price Target?
January 30, 2023
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a
Via
MarketBeat
Exposures
Product Safety
National Advertising Division Finds Novartis Breast Cancer Drug Claim Supported in Physician-Directed Messaging, But Not in Ads to Consumers
January 19, 2023
Via
iCrowdNewswire
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
December 19, 2022
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum
Via
MarketBeat
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
November 30, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END
Via
FinancialNewsMedia
Four Healthcare Stocks To Watch This Week
November 16, 2022
Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.
Via
MarketBeat
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
November 16, 2022
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
November 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...
Via
FinancialNewsMedia
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
October 27, 2022
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all...
Via
MarketBeat
Akouos (NASDAQ: AKUS) Enters Into Agreement to be Acquired by Eli Lilly (NYSE: LLY) at Valuation Up to $610 Million
October 18, 2022
Akouos, Inc. (NASDAQ: AKUS) is engaged as a precision genetic medicine company, which is focused on the research and development
Via
Spotlight Growth
Exposures
Product Safety
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
October 13, 2022
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target.
Via
MarketBeat
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
October 06, 2022
Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates
Via
MarketBeat
Exposures
Product Safety
Highest Gross Margin in the Drug Manufacturers Industry Detected in Shares of Bristol-Myers Squibb Company (BMY, LLY, ZOM, BHC, ABBV)
September 07, 2022
Via
Investor Brand Network
Is Sanofi A Buy, Despite Recent Stumbles?
August 19, 2022
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
August 18, 2022
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds...
Via
TheNewswire.com
Exposures
Product Safety
Are Medtronic And Intuitive Surgical Poised For Big Growth?
August 09, 2022
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Amphetamine Drug Market 2022: Industry Analysis, Size, Global Trends, Share, Growth, Opportunity and Forecast to 2028
July 28, 2022
Amphetamine Drug Market SWOT Analysis Including Key Players Pfizer, Novartis, Eli Lilly, GSK, Hisamitsu Pharmaceutical, Purdue Pharma
Via
SBWire
Global Liposarcoma Treatment Market 2022 Business Strategies and Overview Report 2031 Taro Pharmaceuticals, Sandoz, Pfizer, Eli Lilly, Sanofi SA, Novartis AG
July 13, 2022
The intelligent report on the global Liposarcoma Treatment market provides deep analysis of the Liposarcoma Treatment industry segments including product type, application, special geographies and...
Via
SBWire
Topics
Supply Chain
Exposures
Supply Chain
Medical Stocks Bucking the Bear Trend on Positive News (WHSI, IVC, SPOM, BIMI, RVVTF)
July 07, 2022
Via
AB Newswire
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.